Vous êtes ici

Transgene and Jennerex Announce First Patient Treated in Phase 1/2 Clinical Trial of JX594/TG6006 in Combination with C...

San Francisco, California and Strasbourg, France - Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX594 in patients with whose metastatic colorectal cancer has become refractory to...

Partager